Dosing & Uses
Dosage Forms & Strengths
50 mg/day PO (25 mg/day in patients with possible intravascular depletion or receiving diuretics)
Dosage range: 25-100 mg/day PO in 1 or 2 daily doses
Type 2 diabetes and hypertension: 50-100 mg PO qDay
Hypertension and Left Ventricular Hypertrophy
50 mg PO qDay initially; may increase to 100 mg PO qDay; may use in combination with a thiazide diuretic
Marfan Syndrome (Orphan)
Orphan designation for treatment of Marfan syndrome
- National Marfan Foundation, 22 Manhasset Ave, Port Washington, NY 11050
Generally, adjust dosage monthly; adjust more aggressively in high-risk patients
Serious - Use Alternative
Significant - Monitor Closely
Urinary tract infection (UTI) (13%)
Chest pain (12%)
Cough; incidence higher in previous cough related to angiotensin-converting enzyme (ACE) inhibitor therapy (3-11%)
Upper respiratory tract infection (8%)
Frequency Not Defined
Hypotension in hypovolemic or diuretic-using patients
Worsening renal failure
Black Box Warnings
Discontinue as soon as possible when pregnancy is detected; drug affects renin-angiotensin system, causing oligohydramnios, which may result in fetal injury or death (see Pregnancy & Lactation)
Coadministration with aliskiren in patients with diabetes mellitus
Angioedema, volume-depletion, severe congestive heart failure (CHF), hepatic or renal impairment
Correct volume or salt depletion prior to administration
Increases risks of hypotension; hyperkalemia
Monitor renal function and potassium in susceptible patients
Discontinue immediately if patient is pregnant; potential risk of congenital malformations
Use with caution in renal artery stenosis; avoid in bilateral renal artery stenosis
Renal impairment reported
Increased heart failure-related morbidity in patients receiving ACE inhibitors and beta blockers concomitantly; such combination therapy is not recommended
Dual blockade of the renin-angiotensin-aldosterone system (ie, an angiotensin-receptor blocker [ARB] plus an ACE inhibitor) in patients with established atherosclerotic disease, heart failure, or diabetes with end-organ damage is associated with a higher frequency of hypotension, syncope, hyperkalemia, and altered renal function (including acute renal failure) in comparison with use of a single renin-angiotensin-aldosterone system agent; limit dual blockade to individually defined cases with close monitoring of renal function; closely monitor blood pressure
Risk of anaphylactic reactions or angioedema
Pregnancy & Lactation
Pregnancy category: D
Use of drugs that act on the renin-angiotensin system during the 2nd and 3rd trimesters of pregnancy reduces renal function and increases fetal and neonatal morbidity and death
Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations
Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death
When pregnancy is detected, discontinue as soon as possible
Lactation: Unknown if excreted in milk; not recommended
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Blocks binding of angiotensin II to type 1 angiotensin II receptors; blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II
Onset: 6 hr
Duration: 24 hr
Peak plasma time: 1-1.5 hr
Protein bound: Losartan, 98.7%; E-3174, 99.8%
Vd: Losartan, 34 L; E-3174, 12 L
Metabolized by hepatic P450 enzyme CYP2C9
Metabolites: 5-Carboxylic acid (E-3174) (active metabolite; 40 times as potent as losartan in angiotensin II-blocking activity)
Half-life: Losartan, 1.5-2 hr; E-3174, 6-9 hr; increased in end-stage renal failure or CHF
Dialyzable: HD, no; PD, no
Renal clearance: Losartan, 43-75 mL/min; E-3174, 18-25 mL/min
Total plasma clearance: Losartan, 600 mL/min; E-3174, 50 mL/min
Excretion: Urine (4%)
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.